Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 131 clinical trials
featured
  • 74 views
  • 08 Nov, 2020
  • 1 location
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low

  • 35 views
  • 17 Jan, 2021
  • 183 locations
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.

fluoropyrimidine
irinotecan
bevacizumab
liver metastasis
neutrophil count
  • 0 views
  • 25 Jan, 2021
  • 38 locations
A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC)

and its active metabolites, anti-tumor activity of TAK-788 in participants with NSCLC with epidermal growth factor receptor (EGFR) or human epidermal growth factor 2 (HER2) mutations, explore

systemic therapy
epidermal growth factor receptor
metastasis
epidermal growth factor
stage iv non-small cell lung cancer
  • 0 views
  • 31 Dec, 2020
  • 98 locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

  • 50 views
  • 28 Dec, 2020
  • 199 locations
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to the sequence …

metastasis
liver metastases
lhrh agonist
endocrine therapy
breast cancer
  • 71 views
  • 23 Jan, 2021
  • 72 locations
  • 0 views
  • 04 Nov, 2020
  • 1 location
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or

immunohistochemistry
neutrophil count
platelet count
carcinoma
carcinoma in situ
  • 0 views
  • 24 Jan, 2021
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2

epidermal growth factor receptor
estrogen
trastuzumab
epidermal growth factor
progesterone
  • 0 views
  • 24 Jan, 2021
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2

cish
PIK3CA
human epidermal growth factor
epidermal growth factor
her2-negative breast cancer
  • 0 views
  • 24 Dec, 2020
  • 4 locations